Skip to content

ALNYLAM PHARMACEUTICALS, INC.

ALNY

CIK 0001178670

← back to feed
Revenue (TTM)
$3.12B
+65.2% YoY FY Feb 2026
Net Income (TTM)
$15.76M
+55.2% YoY FY Feb 2026
EPS Diluted (TTM)
$0.02
+54.3% YoY FY Feb 2026
Gross Margin
84.2%
FY Feb 2026
Operating Margin
9.4%
FY Feb 2026
Net Margin
0.5%
FY Feb 2026
Free Cash Flow (TTM)
−$591.19M
FY Feb 2026
Cash
$1.66B
FY Feb 2026
Total Debt
$677.72M
FY Feb 2026
Shares Outstanding
132.62M sh
FY Feb 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings